EA033007B1 - ПОЛИПЕПТИД, СОДЕРЖАЩИЙ ЛИПИДИРОВАННЫЙ ГЕТЕРОДИМЕР МУТАНТНЫХ ФРАГМЕНТОВ OspA, СПОСОБ ПОЛУЧЕНИЯ ПОЛИПЕПТИДА И ЕГО ПРИМЕНЕНИЯ - Google Patents

ПОЛИПЕПТИД, СОДЕРЖАЩИЙ ЛИПИДИРОВАННЫЙ ГЕТЕРОДИМЕР МУТАНТНЫХ ФРАГМЕНТОВ OspA, СПОСОБ ПОЛУЧЕНИЯ ПОЛИПЕПТИДА И ЕГО ПРИМЕНЕНИЯ

Info

Publication number
EA033007B1
EA033007B1 EA201590162A EA201590162A EA033007B1 EA 033007 B1 EA033007 B1 EA 033007B1 EA 201590162 A EA201590162 A EA 201590162A EA 201590162 A EA201590162 A EA 201590162A EA 033007 B1 EA033007 B1 EA 033007B1
Authority
EA
Eurasian Patent Office
Prior art keywords
polypeptide
ospa
lipidated
heterodimer
producing
Prior art date
Application number
EA201590162A
Other languages
English (en)
Russian (ru)
Other versions
EA201590162A1 (ru
Inventor
Пер Комстедт
Урбан Лундберг
Андреас Майнке
Маркус Ханнер
Вольфганг Шюлер
Бенджамин Вайзел
Кристоф Райниш
Брижитт Громанн
Роберт Шлегль
Original Assignee
Валнева Аустриа Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Валнева Аустриа Гмбх filed Critical Валнева Аустриа Гмбх
Publication of EA201590162A1 publication Critical patent/EA201590162A1/ru
Publication of EA033007B1 publication Critical patent/EA033007B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1207—Gram-negative bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
EA201590162A 2012-07-06 2013-07-08 ПОЛИПЕПТИД, СОДЕРЖАЩИЙ ЛИПИДИРОВАННЫЙ ГЕТЕРОДИМЕР МУТАНТНЫХ ФРАГМЕНТОВ OspA, СПОСОБ ПОЛУЧЕНИЯ ПОЛИПЕПТИДА И ЕГО ПРИМЕНЕНИЯ EA033007B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261668627P 2012-07-06 2012-07-06
US13/802,991 US8986704B2 (en) 2012-07-06 2013-03-14 Mutant fragments of OspA and methods and uses relating thereto
PCT/EP2013/064403 WO2014006226A1 (en) 2012-07-06 2013-07-08 MUTANT FRAGMENTS OF OspA AND METHODS AND USES RELATING THERETO

Publications (2)

Publication Number Publication Date
EA201590162A1 EA201590162A1 (ru) 2015-06-30
EA033007B1 true EA033007B1 (ru) 2019-08-30

Family

ID=49878705

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201590162A EA033007B1 (ru) 2012-07-06 2013-07-08 ПОЛИПЕПТИД, СОДЕРЖАЩИЙ ЛИПИДИРОВАННЫЙ ГЕТЕРОДИМЕР МУТАНТНЫХ ФРАГМЕНТОВ OspA, СПОСОБ ПОЛУЧЕНИЯ ПОЛИПЕПТИДА И ЕГО ПРИМЕНЕНИЯ
EA201991059A EA201991059A1 (ru) 2012-07-06 2013-07-08 МУТАНТНЫЕ ФРАГМЕНТЫ OspA И СВЯЗАННЫЕ С НИМИ СПОСОБЫ И ПРИМЕНЕНИЕ

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201991059A EA201991059A1 (ru) 2012-07-06 2013-07-08 МУТАНТНЫЕ ФРАГМЕНТЫ OspA И СВЯЗАННЫЕ С НИМИ СПОСОБЫ И ПРИМЕНЕНИЕ

Country Status (24)

Country Link
US (9) US8986704B2 (enExample)
EP (3) EP2869839B1 (enExample)
JP (1) JP6276258B2 (enExample)
KR (2) KR102190981B1 (enExample)
CN (2) CN104487084B (enExample)
AU (2) AU2013285364B2 (enExample)
CA (1) CA2876541C (enExample)
CY (1) CY1120772T1 (enExample)
DK (1) DK2869839T3 (enExample)
EA (2) EA033007B1 (enExample)
ES (2) ES2800873T3 (enExample)
HR (1) HRP20181689T1 (enExample)
HU (1) HUE041286T2 (enExample)
LT (1) LT2869839T (enExample)
MX (2) MX391136B (enExample)
NZ (2) NZ733026A (enExample)
PL (1) PL2869839T3 (enExample)
PT (1) PT2869839T (enExample)
RS (1) RS57847B1 (enExample)
SI (1) SI2869839T1 (enExample)
SM (1) SMT201800557T1 (enExample)
TR (1) TR201815419T4 (enExample)
WO (1) WO2014006226A1 (enExample)
ZA (1) ZA201409222B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8986704B2 (en) 2012-07-06 2015-03-24 Valneva Austria Gmbh Mutant fragments of OspA and methods and uses relating thereto
MX369195B (es) * 2014-01-09 2019-10-31 Valneva Austria Gmbh Fragmentos mutantes de ospa y métodos y usos relacionados con estos.
WO2015199234A1 (ja) * 2014-06-27 2015-12-30 宇部興産株式会社 ハロゲン置換へテロ環化合物の塩
WO2016022958A2 (en) * 2014-08-07 2016-02-11 The Trustees Of Columbia University In The City Of New York Tick-associated virus sequences and uses thereof
WO2017108902A1 (en) * 2015-12-23 2017-06-29 Novartis Ag Oil-in-water emulsions including retinoic acid
US11345969B2 (en) 2016-02-11 2022-05-31 The Translational Genomics Research Institute Systems and methods for the detection of infectious diseases
WO2018189372A1 (en) 2017-04-13 2018-10-18 Valneva Austria Gmbh Multivalent ospa polypeptides and methods and uses relating thereto
KR20190001421U (ko) 2019-05-26 2019-06-13 이준형 노크형 내부 수납식 칫솔
CN110483624B (zh) * 2019-08-22 2021-02-09 中国疾病预防控制中心传染病预防控制所 伽氏疏螺旋体OspA蛋白C端肽段及其应用
CN111269919B (zh) * 2020-03-19 2021-07-13 四川农业大学 玉米基因ZmLIP2及其应用
IL297166A (en) * 2020-04-09 2022-12-01 Valneva Austria Gmbh Compositions comprising three ospa fusion proteins for medical use
US20240026412A1 (en) * 2020-04-09 2024-01-25 Valneva Austria Gmbh Improved methods of producing a lipidated protein
WO2023034932A1 (en) * 2021-09-02 2023-03-09 Vaxcyte, Inc. Stabilization of adjuvanted vaccine compositions and their use
EP4743110A1 (en) 2023-07-10 2026-05-20 Dynavax Technologies Corporation Lyme disease vaccines containing an adjuvant and Borrelia outer surface protein A and C antigens
JP2026525284A (ja) 2023-07-10 2026-07-29 ダイナヴァックス テクノロジーズ コーポレイション アジュバントおよびｂｏｒｒｅｌｉａ細胞表層タンパク質ａ抗原を含むライム病ワクチン

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008031133A2 (en) * 2006-09-15 2008-03-20 Intercell Ag Borrelia antigens
WO2011143617A1 (en) * 2010-05-14 2011-11-17 Baxter International Inc. Chimeric ospa genes, proteins, and methods of use thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248562B1 (en) 1993-11-01 2001-06-19 Research Foundation State University Of New York Chimeric proteins comprising borrelia polypeptides and uses therefor
US7008625B2 (en) * 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
EP1311540B1 (en) * 2000-08-18 2007-12-19 Research Foundation Of State University Of New York Altered ospa of borrelia burgdorferi
UA89481C2 (uk) * 2003-09-30 2010-02-10 Центокор, Инк. Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування
EP2468300B1 (en) * 2006-09-26 2017-12-20 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US8466259B2 (en) 2007-12-07 2013-06-18 National Health Research Institutes Adjuvants
TWI376385B (en) 2007-12-07 2012-11-11 Nat Health Research Institutes Production of lipidated proteins in e. coli
EP2470664A4 (en) 2009-08-27 2013-01-16 Synaptic Res Llc NEW PROTEIN RELEASE SYSTEM FOR GENERATING INDUCED PLURIPOTENTAL STEM CELLS OR TISSUE-SPECIFIC CELLS
KR101907434B1 (ko) 2010-09-03 2018-10-12 발네바 오스트리아 게엠베하 C. 디피실의 a 독소 및 b 독소 단백질의 분리된 폴리펩타이드 및 이의 용도
TWI507413B (zh) 2010-11-15 2015-11-11 Nat Health Research Institutes 脂質化多抗原表位疫苗
TW201221642A (en) 2010-11-15 2012-06-01 Nat Health Research Institutes Method of producing lipidated polypeptides
US9925257B2 (en) 2011-09-23 2018-03-27 Forsyth Dental Infirmary For Children Vaccine and therapeutic delivery system
CN103974834B (zh) 2011-12-06 2017-09-05 慕贝尔碳纤维技术有限公司 由纤维增强材料制造的车轮及制造相应车轮的方法
EP4400115A3 (en) 2011-12-06 2024-10-23 Valneva Austria GmbH Aluminium compounds for use in therapeutics and vaccines
US8986704B2 (en) 2012-07-06 2015-03-24 Valneva Austria Gmbh Mutant fragments of OspA and methods and uses relating thereto
MX369195B (es) 2014-01-09 2019-10-31 Valneva Austria Gmbh Fragmentos mutantes de ospa y métodos y usos relacionados con estos.
CZ2014320A3 (cs) 2014-05-09 2015-11-18 VÝZKUMNÝ ÚSTAV VETERINÁRNÍHO LÉKAŘSTVÍ, v.v.i. Polyepitopový antigen, vakcinační konstrukt a vakcína pro prevenci lymeské boreliózy
JP6947727B2 (ja) 2015-12-10 2021-10-13 ナショナル リサーチ カウンシル オブ カナダ 脂質化肺炎球菌抗原組成物、調製方法及び使用
WO2018189372A1 (en) 2017-04-13 2018-10-18 Valneva Austria Gmbh Multivalent ospa polypeptides and methods and uses relating thereto
WO2019092002A1 (en) 2017-11-07 2019-05-16 Valneva Se Pharmaceutical compositions for treatment or prevention of viral infections
KR20220010478A (ko) 2019-05-20 2022-01-25 발네바 에스이 기도 감염의 치료 또는 예방용 서브유닛 백신
CR20220552A (es) 2020-04-02 2023-01-17 Regeneron Pharma Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno
US20240026412A1 (en) 2020-04-09 2024-01-25 Valneva Austria Gmbh Improved methods of producing a lipidated protein
IL297166A (en) 2020-04-09 2022-12-01 Valneva Austria Gmbh Compositions comprising three ospa fusion proteins for medical use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008031133A2 (en) * 2006-09-15 2008-03-20 Intercell Ag Borrelia antigens
WO2011143617A1 (en) * 2010-05-14 2011-11-17 Baxter International Inc. Chimeric ospa genes, proteins, and methods of use thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DEBORAH FASS: "Disulfide Bonding in Protein Biophysics", ANNUAL REVIEW OF BIOPHYSICS, ANNUAL REVIEWS, vol. 41, no. 1, 9 June 2012 (2012-06-09), pages 63 - 79, XP055080113, ISSN: 1936122X, DOI: 10.1146/annurev-biophys-050511-102321 *
DING, W. HUANG, X. YANG, X. DUNN, J.J. LUFT, B.J. KOIDE, S. LAWSON, C.L.: "Structural identification of a key protective B-cell epitope in lyme disease antigen OspA", JOURNAL OF MOLECULAR BIOLOGY, ACADEMIC PRESS, UNITED KINGDOM, vol. 302, no. 5, 6 October 2000 (2000-10-06), United Kingdom, pages 1153 - 1164, XP004472344, ISSN: 0022-2836, DOI: 10.1006/jmbi.2000.4119 *
HERTADI, R. ; GRUSWITZ, F. ; SILVER, L. ; KOIDE, A. ; KOIDE, S. ; ARAKAWA, H. ; IKAI, A.: "Unfolding Mechanics of Multiple OspA Substructures Investigated with Single Molecule Force Spectroscopy", JOURNAL OF MOLECULAR BIOLOGY, ACADEMIC PRESS, UNITED KINGDOM, vol. 333, no. 5, 7 November 2003 (2003-11-07), United Kingdom, pages 993 - 1002, XP027101255, ISSN: 0022-2836, DOI: 10.1016/j.jmb.2003.09.010 *
KOIDE, S. YANG, X. HUANG, X. DUNN, J.J. LUFT, B.J.: "Structure-based Design of a Second-generation Lyme Disease Vaccine Based on a C-terminal Fragment of Borrelia burgdorferi OspA", JOURNAL OF MOLECULAR BIOLOGY, ACADEMIC PRESS, UNITED KINGDOM, vol. 350, no. 2, 8 July 2005 (2005-07-08), United Kingdom, pages 290 - 299, XP004927295, ISSN: 0022-2836, DOI: 10.1016/j.jmb.2005.04.066 *
LI H ET AL: "Crystal structure of Lyme disease antigen outer surface protein A complexed with an Fab.", NATIONAL ACADEMY OF SCIENCES, US, vol. 94, no. 8, 15 April 1997 (1997-04-15), US, pages 3584 - 3589, XP002456095, ISSN: 0027-8424, DOI: 10.1073/pnas.94.8.3584 *
VAN HOECKE, C. COMBERBACH, M. DE GRAVE, D. DESMONS, P. FU, D. HAUSER, P. LEBACQ, E. LOBET, Y. VOET, P.: "Evaluation of the safety, reactogenicity and immunogenicity of three recombinant outer surface protein (OspA) lyme vaccines in healthy adults", VACCINE, ELSEVIER, AMSTERDAM, NL, vol. 14, no. 17, 1 December 1996 (1996-12-01), AMSTERDAM, NL, pages 1620 - 1626, XP004016822, ISSN: 0264-410X, DOI: 10.1016/S0264-410X(96)00146-6 *

Also Published As

Publication number Publication date
KR102190981B1 (ko) 2020-12-15
US20150250865A1 (en) 2015-09-10
HK1207982A1 (en) 2016-02-19
JP2015522270A (ja) 2015-08-06
EA201991059A1 (ru) 2020-01-31
LT2869839T (lt) 2018-11-12
US8986704B2 (en) 2015-03-24
HK1257893A1 (en) 2019-11-01
EP2869839A1 (en) 2015-05-13
US20200239525A1 (en) 2020-07-30
EP2869839B1 (en) 2018-09-05
SI2869839T1 (sl) 2018-11-30
PL2869839T3 (pl) 2018-12-31
KR20150036191A (ko) 2015-04-07
HK1209370A1 (en) 2016-04-01
US11208439B2 (en) 2021-12-28
KR20200141096A (ko) 2020-12-17
CN104487084B (zh) 2017-09-22
US20140010835A1 (en) 2014-01-09
HRP20181689T1 (hr) 2018-12-28
EP3360568B1 (en) 2020-03-04
RS57847B1 (sr) 2018-12-31
AU2017218974A1 (en) 2017-09-07
SMT201800557T1 (it) 2018-11-09
ES2688883T3 (es) 2018-11-07
US20230295245A1 (en) 2023-09-21
PT2869839T (pt) 2018-11-12
US11466058B2 (en) 2022-10-11
EA201590162A1 (ru) 2015-06-30
US20180327460A1 (en) 2018-11-15
AU2017218974C1 (en) 2020-02-20
US20170107263A1 (en) 2017-04-20
AU2013285364A1 (en) 2015-01-29
JP6276258B2 (ja) 2018-02-07
EP3689372A1 (en) 2020-08-05
TR201815419T4 (tr) 2018-11-21
MX2015000013A (es) 2015-06-04
US12195501B2 (en) 2025-01-14
US20150232517A1 (en) 2015-08-20
CA2876541C (en) 2022-03-01
HK1248244A1 (zh) 2018-10-12
CA2876541A1 (en) 2014-01-09
US9926343B2 (en) 2018-03-27
EP3360568A1 (en) 2018-08-15
AU2013285364B2 (en) 2017-06-15
WO2014006226A1 (en) 2014-01-09
US10544194B2 (en) 2020-01-28
DK2869839T3 (en) 2018-10-15
NZ703597A (en) 2017-06-30
CY1120772T1 (el) 2019-12-11
ES2800873T3 (es) 2021-01-04
ZA201409222B (en) 2016-08-31
US20220185851A1 (en) 2022-06-16
CN107602676A (zh) 2018-01-19
NZ733026A (en) 2019-09-27
EP3689372B1 (en) 2026-04-29
MX391136B (es) 2025-03-21
CN107602676B (zh) 2021-06-04
HUE041286T2 (hu) 2019-05-28
MX364623B (es) 2019-05-03
CN104487084A (zh) 2015-04-01
AU2017218974B2 (en) 2019-05-30
KR102393038B1 (ko) 2022-04-29
US20170101446A1 (en) 2017-04-13

Similar Documents

Publication Publication Date Title
NZ703597A (en) Mutant fragments of ospa and methods and uses relating thereto
NZ603901A (en) Vectors and sequences for the treatment of diseases
NZ721015A (en) Mutant fragments of ospa and methods and uses relating thereto
MX2022005291A (es) Vacunas para el tratamiento y prevencion del cancer.
MX2015000338A (es) Novedosa cepa de lactobacillus crispatus.
MX2020010399A (es) 3-epimerasa.
MX2009010800A (es) Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos.
IN2015KN00414A (enExample)
WO2010034032A3 (en) Methods for preparing purified polypeptide compositions
EP4414376A3 (en) Novel depsipeptide and uses thereof
WO2011112867A8 (en) The use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas
GB201118201D0 (en) Novel peptides
FI3564378T3 (fi) Immunogeeninen koostumus
MX2019000346A (es) Metodos y composiciones para el tratamiento del cancer.
NZ602693A (en) Immunogenic proteins and compositions for the treatment and prevention of streptococcus agalactiae
MY193807A (en) T-cell receptor and uses thereof
MX357071B (es) Medicamentos que comprenden apolipoproteína a-iv no glicosilada para el tratamiento de diabetes.
NZ700467A (en) Treatments suitable for malassezia infections
NZ729514A (en) Therapeutic multi-peptides t specific immune therapy for treatment of brain metastasis
NZ614255A (en) Vaccine compositions and methods for treatment of mucormycosis and other fungal diseases
WO2015054439A3 (en) Hybrid factor viii polypeptides for use to treat hemophilia a
PH12013501105A1 (en) Tomm34 peptides and vaccines including the same
WO2015048785A3 (en) Mosaic conserved region hiv immunogenic polypeptides
NZ707753A (en) Purification of recombinant human galactocerebroside β-galactosidase (rhgalc)
WO2013158818A3 (en) Vaccines and methods to treat lyme disease in dogs